Physician profile
Jennifer Joy Pendleton
NPI 1821054446
$11,833.55
in general payments reported to CMS, 2019-2025
40 companies · $2,973 in 2025
The $2,973 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $426 · 2021: $890 · 2022: $2,577 · 2023: $1,437 · 2024: $1,872 · 2025: $2,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,267 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,266.85 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,180.84 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,045.45 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $996.51 | 2019-2025 | |
| Amgen INC. | $699.92 | 2021-2025 | Tezspire, Evenity, Tepezza |
| Pfizer INC. | $590.82 | 2019-2025 | |
| Genentech USA, INC. | $492.57 | 2021-2025 | Xolair |
| Grifols USA, LLC | $456.57 | 2022-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $413.08 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $410.92 | 2019-2025 | |
| Optinose US, INC. | $387.92 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $335.97 | 2021-2025 | Eohilia, Takhzyro, Cuvitru |
| Incyte Corporation | $283.19 | 2021-2025 | Opzelura |
| Csl Behring | $280.73 | 2019-2025 | Hizentra |
| Kaleo, INC. | $224.96 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $192.85 | 2019-2025 | Ragwitek, Odactra, Grastek |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.